Clinical efficacy and safety of ziprasidone and risperidone in the treatment of schizophrenia
10.13699/j.cnki.1001-6821.2015.10.013
- VernacularTitle:齐拉西酮和利培酮治疗精神分裂症的临床疗效及安全性评价
- Author:
Tong-Xian CHEN
1
;
Yao-Yu YAN
;
You-Yuan BAO
Author Information
1. 台州市第二人民医院 精神科
- Keywords:
schizophrenia;
risperidone;
ziprasidone;
clinical effects;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2015;(10):809-811
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of ziprasidone versus risperidone in the treatment of schizophrenia .Methods A total of 120 patients with schizophrenia were randomly divided into treatment group (n=62) and control group(n=58).Patients in the control group were administered risperidone 0.25 mg? d-1 initially with maximum of 4.0 mg? d-1 orally, qd. And patients in the treatment group were administered of ziprasidone 40 mg? d -1 initially with maximum of 160 mg? d-1 orally, bid.All the patients received 8 weeks treatment.After treatment, the clinical efficacy ,quality of life score and side effects were compared between the two groups.Results After treatment, the clinical efficacy were 89.66% and 91.94% in control and treatment group respectively, with no statistical difference(P>0.05).The score evalua-ted by the short from health survey ( SF-36 ) was significant higher in treatment group compared with control group ( P <0.05 ) . The side effects incidence rate were 20.69% in control group and 8.06% in treatment group, which was significantly difference ( P <0.05 ) . Conclusion The clinical efficacy was not different between ziprasidone and risperidone.But ziprasidone can improve patients′quality of life much more significantly with and less adverse events .
